Induction of proteinuria by cannabinoid receptors 1 signaling activation in CB1 transgenic mice

American Journal of the Medical Sciences

Volumn 349, Issue 2, 2015, Pages 162-168

  Hsu, Yung Chien ^a   Lei, Chen Chou ^a   Shih, Ya Hsueh ^a   Ho, Cheng ^a   Lin, Chun Liang ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Nephrin; Proteinuria; Type 1 cannabinoid receptors

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; GLUCOSE; NEPHRIN; PROTEIN; VASCULOTROPIN; ANALGESIC AGENT; BENZOXAZINE DERIVATIVE; GLUCOSE BLOOD LEVEL; MEMBRANE PROTEIN; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLOMERULOPATHY; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY MASS; LASER CAPTURE MICRODISSECTION; MALE; MOUSE; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION; VALIDATION STUDY; WILD TYPE; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY DISEASE; MESANGIUM; METABOLISM; ORGAN SIZE; PATHOLOGY; WISTAR RAT;

ANALGESICS; ANIMALS; BENZOXAZINES; BLOOD GLUCOSE; GENE EXPRESSION REGULATION; GLOMERULAR MESANGIUM; HUMANS; KIDNEY DISEASES; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MORPHOLINES; NAPHTHALENES; ORGAN SIZE; PROTEINURIA; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923640792     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000352     Document Type: Article

References (36)

1. Breyer JA, Bain RP, Evans JK, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996; 50:1651-8
2. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754-62
3. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349: 1857-63
4. Wapstra FH, Navis G, de Jong PE, et al. Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Exp Nephrol 1996;4(suppl 1):47-52
5. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
6. Lindskog A, Ebefors K, Johansson ME, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010;21:1290-8
7. Fujikawa T, Chuang JC, Sakata I, et al. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci USA 2010;107:17391-6
8. Granado M, García-Cáceres C, Frago LM, et al. The positive effects of growth hormone-releasing peptide-6 on weight gain and fat mass accrual depend on the insulin/glucose status. Endocrinology 2010; 151:2008-18
9. Burgess G, Williams D. The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest 2010;120:3753-9
10. Yeh JH, Cheng HH, Huang CJ, et al. Effect of anandamide on cytosolic Ca(2+) levels and proliferation in canine renal tubular cells. Basic Clin Pharmacol Toxicol 2006;98:416-22
11. Koura Y, Ichihara A, Tada Y, et al. Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys. J Am Soc Nephrol 2004;15:1488-94
12. Csóka B, Németh ZH, Mukhopadhyay P, et al. CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. PLoS One 2009;4:e6409
13. Mukhopadhyay P, Rajesh M, Pan H, et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 2010;48:457-67
14. Feizi A, Jafari MR, Hamedivafa F, et al. The preventive effect of cannabinoids on reperfusion-induced ischemia of mouse kidney. Exp Toxicol Pathol 2008;60:405-10
15. Domenicali M, Caraceni P, Giannone F, et al. Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. Gastroenterology 2009;137:341-9
16. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006;12:671-6
17. Janiak P, Poirier B, Bidouard JP, et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 2007;72:1345-57
18. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374:1383-91
19. Vupputuri S, Batuman V, Muntner P, et al. The risk for mild kidney function decline associated with illicit drug use among hypertensive men. Am J Kidney Dis 2004;43:629-35
20. Barutta F, Corbelli A, Mastrocola R, et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010;59:1046-54
21. Hsiao YC, Chang HH, Tsai CY, et al. Coat color-tagged green mouse with EGFP expressed from the RNA polymerase II promoter. Genesis 2004;39:122-9
22. Lin CL, Wang JY, Ko JY, et al. Dickkopf-1 promotes hyperglycemiainduced accumulation of mesangial matrix and renal dysfunction. J Am Soc Nephrol 2010;21:124-35
23. Zhang F, Hong S, Stone V, et al. Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 2007;323:508-15
24. El-Remessy AB, Rajesh M, Mukhopadhyay P, et al. Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia 2011;54:1567-78
25. Rajesh M, Bátkai S, Kechrid M, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012;61:716-27
26. Vupputuri S, Batuman V, Muntner P, et al. The risk for mild kidney function decline associated with illicit drug use among hypertensive men. Am J Kidney Dis 2004;43:629-35
27. Li Y, Sun Y, Zhang Z, et al. Cannabinoid receptors 1 and 2 are associated with bladder dysfunction in an experimental diabetic rat model. BJU Int 2013;112:E143-50
28. Vera G, López-Miranda V, Herradón E, et al. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes. Pharmacol Biochem Behav 2012;102:335-43
29. Wang R, Hu W, Qiang L. G1359A polymorphism in the cannabinoid receptor-1 gene is associated with the presence of coronary artery disease in patients with type 2 diabetes. J Investig Med 2012;60:44-8
30. Qi Z, Fujita H, Jin J, et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005;54:2628-37
31. Bifulco M, Di Marzo V. The endocannabinoid system as a target for the development of new drugs for cancer therapy. Recenti Prog Med 2003;94:194-8
32. Pisanti S, Malfitano AM, Grimaldi C, et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab 2009;23:117-31
33. Pisanti S, Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 2009;60:107-16
34. Pisanti S, Picardi P, Prota L, et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 2011;117:5541-50
35. Rubovitch V, Gafni M, Sarne Y. The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 2004;120: 138-44
36. Argaw A, Duff G, Zabouri N, et al. Concerted action of CB1 cannabinoid receptor and deleted in colorectal cancer in axon guidance. J Neurosci 2011;31:1489-99